0.00Open0.00Pre Close0 Volume0 Open Interest5.00Strike Price0.00Turnover928.17%IV-304.86%PremiumDec 20, 2024Expiry Date3.77Intrinsic Value100Multiplier8DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.6279Delta0.2230Gamma0.30Leverage Ratio-0.0401Theta-0.0008Rho-0.19Eff Leverage0.0007Vega
Actinium Stock Discussion
PR Newswire· 10 mins ago
SK Biopharmaceuticals, Korea Institute of Radiological and Medical Sciences collaborate on discovering and developing radiopharmaceutical drug candidates using an alpha-particleemittingradioisotope, actinium-225, for potential cancer treatm...
Actinium Announces Publication Of Phase 3 SIERRA Results Of Iomab-B - Quick Facts
Good lesson on the higher risks of biologics though. BLA (biologics license application) a relatively new classification (maybe 5 or so years?) meant to divert biologics from the NDA process that small molecule drugs go through.
In practical terms,...
Actinium Pharmaceuticals Inc - Iomab-B Well Tolerated in Older Relapsed/Refractory Aml Patients
September 05, 2024 08:00 AM Eastern Daylight Time!!! From this morning! BUT THIS ONE BELOW JUST WAS RELEASED VIA SEEKING ALPHA! NOT SURE IF THEY ARE MISPRINT OF DRUG? OR ANOTHER APPROVAL?
Perspective gets FDA fast track status for radiopharmaceutical VMT101
No comment yet